{"id":"ve303","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Abdominal pain"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"VE303 works by introducing a combination of live microbes into the gut to restore a balanced microbiome, which helps to reduce inflammation and promote healing in the gastrointestinal tract.","oneSentence":"VE303 is a live biotherapeutic product that modulates the gut microbiome to treat inflammatory bowel disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:21.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT06237452","phase":"PHASE3","title":"VE303 for Prevention of Recurrent Clostridioides Difficile Infection","status":"RECRUITING","sponsor":"Vedanta Biosciences, Inc.","startDate":"2024-05-20","conditions":"Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence","enrollment":852},{"nctId":"NCT04899115","phase":"PHASE2","title":"VE303 for Treatment of Hepatic Encephalopathy (HE)","status":"COMPLETED","sponsor":"Patricia Bloom","startDate":"2021-08-06","conditions":"Cirrhosis, Hepatic Encephalopathy","enrollment":19},{"nctId":"NCT03788434","phase":"PHASE2","title":"Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Vedanta Biosciences, Inc.","startDate":"2019-02-08","conditions":"Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile","enrollment":79},{"nctId":"NCT04236778","phase":"PHASE1","title":"First-in-human Study of VE303 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Vedanta Biosciences, Inc.","startDate":"2017-11-28","conditions":"Healthy Volunteers","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VE303","genericName":"VE303","companyName":"Vedanta Biosciences, Inc.","companyId":"vedanta-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VE303 is a live biotherapeutic product that modulates the gut microbiome to treat inflammatory bowel disease. Used for Moderate to severe ulcerative colitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}